Acromegaly (Hormonal Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly – Drugs In Development, 2021, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 5, 8, 5, 2 and 1 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).

– The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

ASCIL Biopharm

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Enesi Pharma Ltd

Foresee Pharmaceuticals Co Ltd

GeneScience Pharmaceuticals Co Ltd

Genevant Sciences Ltd

GlyTech Inc

Ionis Pharmaceuticals Inc

Italfarmaco SpA

OPKO Health Inc

PeptiDream Inc

Pharmathen Global BV

Rani Therapeutics LLC

Strongbridge Biopharma plc

Table of Contents

Table of Contents

Introduction

Acromegaly - Overview

Acromegaly - Therapeutics Development

Acromegaly - Therapeutics Assessment

Acromegaly - Companies Involved in Therapeutics Development

Acromegaly - Drug Profiles

Acromegaly - Dormant Projects

Acromegaly - Discontinued Products

Acromegaly - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Acromegaly, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Acromegaly – Pipeline by Antisense Therapeutics Ltd, 2021

Acromegaly – Pipeline by Aquestive Therapeutics Inc, 2021

Acromegaly – Pipeline by ASCIL Biopharm, 2021

Acromegaly – Pipeline by Camurus AB, 2021

Acromegaly – Pipeline by Chiasma Inc, 2021

Acromegaly – Pipeline by Crinetics Pharmaceuticals Inc, 2021

Acromegaly – Pipeline by Daewoong Pharmaceutical Co Ltd, 2021

Acromegaly – Pipeline by Dauntless Pharmaceuticals Inc, 2021

Acromegaly – Pipeline by DexTech Medical AB, 2021

Acromegaly – Pipeline by Enesi Pharma Ltd, 2021

Acromegaly – Pipeline by Foresee Pharmaceuticals Co Ltd, 2021

Acromegaly – Pipeline by GeneScience Pharmaceuticals Co Ltd, 2021

Acromegaly – Pipeline by Genevant Sciences Ltd, 2021

Acromegaly – Pipeline by GlyTech Inc, 2021

Acromegaly – Pipeline by Ionis Pharmaceuticals Inc, 2021

Acromegaly – Pipeline by Italfarmaco SpA, 2021

Acromegaly – Pipeline by OPKO Health Inc, 2021

Acromegaly – Pipeline by PeptiDream Inc, 2021

Acromegaly – Pipeline by Pharmathen Global BV, 2021

Acromegaly – Pipeline by Rani Therapeutics LLC, 2021

Acromegaly – Pipeline by Strongbridge Biopharma plc, 2021

Acromegaly – Dormant Projects, 2021

Acromegaly – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Acromegaly, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports